Life Insurance with COPD | Emphysema Life Insurance | High Risk

COPD (chronic obstructive pulmonary disease) and emphysema are among the more challenging conditions in life insurance underwriting because they are progressive and closely tied to smoking history. Mild, well-managed COPD in a former smoker with stable lung function may still qualify for coverage at a table rating; moderate to severe COPD typically results in decline at most fully underwritten carriers. Lung function test results (FEV1/FVC ratio), smoking status, oxygen use, and frequency of exacerbations are the variables that drive everything.

What Underwriters Evaluate for COPD

Every COPD case is reviewed individually. These are the factors that determine whether you qualify, at what rating, and with which carrier:

Pulmonary Function Test Results (PFTs) — The FEV1 (forced expiratory volume) percentage of predicted is the primary metric. FEV1 above 70% (GOLD Stage 1) is viewed most favorably. FEV1 of 50–69% (GOLD Stage 2) typically results in table ratings. Below 50% (GOLD Stage 3–4) results in decline at most standard carriers.

Smoking Status — Current smokers receive tobacco rates on top of COPD ratings, compounding the cost significantly. Former smokers are evaluated more favorably, particularly those who quit several years prior. The length of time since quitting matters to underwriters.

Oxygen Use — Supplemental oxygen use, whether intermittent or continuous, signals more advanced disease and results in decline at virtually all fully underwritten carriers. Guaranteed issue or graded benefit products are typically the only options for oxygen-dependent applicants.

Exacerbation History — Frequent hospitalizations or acute exacerbations within the past 12–24 months are a significant negative. Carriers look for stability — an applicant with COPD who has not been hospitalized and has stable lung function is viewed much more favorably than one with recent flare-ups.

Medications and Compliance — Use of inhaled bronchodilators and inhaled corticosteroids as prescribed is viewed as responsible management. Systemic oral corticosteroid use (prednisone) on a regular basis signals more severe disease and typically worsens the underwriting outcome.

Co-Morbid Conditions — COPD combined with heart disease, pulmonary hypertension, or significant sleep apnea compounds risk substantially. Each condition is evaluated independently, and the combined profile is typically worse than any individual component.

COPD Severity: General Underwriting Outlook

Below is a general guide to how carriers approach COPD based on GOLD staging and clinical presentation.

COPD Profile	Typical Rating	Best Achievable	Notes
GOLD Stage 1 (FEV1 80%+), former smoker, stable	Table 2–4	Table 2 at select carriers	Most favorable COPD presentation; carrier selection important
GOLD Stage 2 (FEV1 50–79%), former smoker, stable	Table 4–8	Table 4 at competitive carriers	Moderate disease; limited but available options
GOLD Stage 1–2, current smoker	Table 4–8 plus tobacco rates	Table 4 with tobacco surcharge	Tobacco rating stacks on top of COPD rating
GOLD Stage 3 (FEV1 30–49%)	Decline at most carriers	Simplified issue or guaranteed issue	Very limited fully underwritten options
GOLD Stage 4 (FEV1 under 30%) or oxygen use	Decline at all standard carriers	Guaranteed issue only	Guaranteed issue with graded benefit is typically the only path
COPD with pulmonary hypertension or heart failure	Decline	Guaranteed issue only	Secondary conditions make standard coverage unavailable

Guidelines current as of 2025–2026. Carrier underwriting guidelines are subject to change. Verify with us before applying.

Carrier Guidelines: COPD Underwriting Comparison

COPD has a narrower field of competitive carriers than most conditions. For mild to moderate disease, a few carriers stand out significantly.

Carrier	Mild COPD (Stage 1)	Moderate COPD (Stage 2)	Notes
Protective Life	Table 2–4 former smoker, stable	Table 4–6	Among the more competitive for mild COPD cases
Prudential	Table 2–4; medical director review for borderline	Table 4–8	Medical director review process beneficial for well-documented mild cases
Banner / Legal & General	Table 4 for mild stable COPD	Table 6–8 or decline	More conservative than Protective; limited appetite for moderate COPD
Pacific Life	Table 2–4 with good PFT results	Table 4–8	Requires recent PFT documentation; competitive for mild cases
Mutual of Omaha	Table 4 for mild COPD	Decline or simplified issue	Strong simplified and guaranteed issue options for those declined elsewhere
Transamerica / North American	Table 4–6 for mild cases	Decline	Limited appetite for COPD; better options exist elsewhere for most profiles

Guidelines current as of 2025–2026. Carrier underwriting guidelines are subject to change. Verify with us before applying.

Situations That Typically Result in Decline

Supplemental Oxygen Use — Any supplemental oxygen use, continuous or intermittent, results in decline at all fully underwritten carriers. Guaranteed issue products with a graded death benefit are the primary remaining option.

GOLD Stage 3–4 (Severe to Very Severe) — FEV1 below 50% of predicted essentially closes the door on standard fully underwritten coverage. A small number of carriers may still consider Stage 3 at very high table ratings, but options are extremely limited.

Recent Hospitalization for Exacerbation — A hospitalization within the past 12–24 months for acute COPD exacerbation triggers postponement at most carriers. Stability over an extended period following hospitalization is required before an application is viable.

COPD with Pulmonary Hypertension — Secondary pulmonary hypertension developing from COPD is a serious complication that results in decline at all standard carriers. This combination effectively limits coverage to guaranteed issue or final expense products.

What You Can Do to Improve Your Outcome

Quit smoking — and document it. If you are a current smoker with COPD, quitting is the single biggest underwriting lever available to you. Carriers provide better rates to former smokers, and the benefit compounds over time. Documentation of cessation is critical.

Get recent pulmonary function tests. Underwriters cannot assess COPD severity without PFT results. Current PFT documentation — ideally within the past 12 months — demonstrating stable or improving lung function is essential for any favorable underwriting consideration.

Avoid hospitalizations as long as possible before applying. If you have been stable and are considering applying, timing matters. A period of documented stability — ideally 12–24 months without hospitalization — significantly improves your underwriting outcome.

Work with a specialist broker for COPD cases. The difference between carriers on COPD can be several table ratings or the difference between being insurable at all versus declined. Applying directly to the wrong carrier with COPD history means a decline that goes on your MIB record.

Have COPD or Emphysema? Let’s Find Your Options.

COPD underwriting varies dramatically by carrier. We know which carriers will consider your profile before any formal application is submitted, protecting your MIB record and maximizing your chances of approval.

Call 1-888-972-0024

Browse All High-Risk Conditions

Understanding Your Rating: Life Insurance Risk Classifications | Table Ratings Explained (B–J) | Flat Extra Ratings

Authoritative Resources: Life insurance underwriting practices are regulated by the NAIC. Insurers may check your health history through the MIB Group — you can request your free annual MIB report at mib.com.

Frequently Asked Questions

Can I get life insurance with COPD?

Yes, in many cases. Mild COPD (GOLD Stage 1, FEV1 above 80%) in a former smoker with stable lung function and no supplemental oxygen use can qualify for table-rated coverage at select carriers. Moderate COPD (Stage 2, FEV1 50–79%) has more limited options but is still insurable at some carriers. Severe COPD or oxygen dependency typically results in decline at fully underwritten carriers.

What pulmonary function test results do I need for life insurance with COPD?

The primary metric underwriters use is FEV1 (forced expiratory volume in one second) as a percentage of predicted. FEV1 above 70–80% is the most favorable range and may qualify for table-rated coverage. FEV1 between 50 and 69% (GOLD Stage 2) has more limited options. Below 50% (GOLD Stage 3) typically results in decline at most standard carriers. Current PFT documentation, ideally within the past 12 months, is essential.

Does smoking history affect COPD life insurance underwriting?

Yes significantly. Current smokers receive tobacco rates on top of COPD ratings, which compounds the cost substantially. Former smokers are evaluated more favorably, particularly those who quit several years prior. Quitting smoking and documenting cessation is the single biggest underwriting lever available to COPD applicants.

Will supplemental oxygen use prevent me from getting life insurance?

Yes. Any supplemental oxygen use — continuous or intermittent — results in decline at all fully underwritten carriers. Guaranteed issue whole life insurance, which has no medical questions and no health requirements, is typically the most accessible coverage option for oxygen-dependent applicants.

Should I use an independent broker for COPD life insurance?

Absolutely. COPD has a narrow field of competitive carriers, and applying to the wrong carrier creates a decline on your MIB record that follows you to future applications. An independent broker can informally shop your case before any formal application is submitted, identifying which carriers are most likely to make a favorable offer for your specific FEV1 level and smoking history.